All News CanSino Biologics Inc. Shanghai S.E.

Equities

688185

CNE100004BM0

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-04 EDT			5-day change	1st Jan Change
48.78 ^CNY	-0.14%		-1.13%	-34.54%

05-31	CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	CI
05-21	Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CanSino Biologics Inc. Announces Resignation of Nisa Bernice Wing-Yu LEUNG as Non-Executive Director and Member of the Nomination Committee	05-31	CI
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	05-21	MT
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	04-29	AQ
CanSinoBIO CSO Shares Latest Results of the Company's Globally Innovative Pneumococcal Vaccine	04-26	AQ
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	04-22	MT
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	04-22	CI
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	04-21	MT
The Commercialization of Asia's First Meningococcal Conjugate Vaccine From CanSinoBIO Represents a Significant Breakthrough	03-27	AQ
CanSino Biologics : CanSinoBIO Initiates Phase Ⅲ Clinical Trial of Group ACYW135 Meningococcal Conjugate Vaccine Menhycia® in Indonesia	03-24	PU
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	03-20	MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	03-20	CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	03-14	MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	02-28	CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	02-26	MT
Cansino Biologics Inc. Announces Board and Committee Elections	02-23	CI
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
CanSino Biologics Deconsolidates CanSino SPH	02-02	MT
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	01-31	MT
CanSino Biologics' 13-Valent Pneumococcal Vaccine Trial Shows Positive Results	01-31	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 06:08 am